Financial Transparency and Efficiency of Prescription, Biosimilar, and Generic Drug User Fee Acts: Public Meeting and Comment Request
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA is holding a public meeting to discuss the financial management of user fee programs related to prescription, biosimilar, and generic drugs. This will include updates on the five-year financial plans, resource capacity planning, and time reporting improvements. Stakeholders are invited to provide feedback by attending the meeting and submitting comments by July 23, 2026.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Public meeting to discuss drug user fee programs
- Updates on five-year financial plans and resource planning
- Invitation for public comments by July 23, 2026
Obligations
What this law requires
Stakeholders must submit comments regarding the financial management of user fee programs by July 23, 2026.
FDA must publish a five-year financial plan and update it annually for the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments.
FDA must continue activities to mature resource capacity planning in regard to fee setting.
FDA must modernize time reporting practices as part of its fee management commitments.
Participants must register for the public meeting by June 12, 2026, at 11:59 p.m. Eastern Time.